Endocrine Surgery Patients' and Providers' Perceptions of Telemedicine in the COVID Era

Posted: 2021-09-15 19:00:00
Background: Telemedicine has become a key modality for health care delivery during the COVID-19 pandemic, including for endocrine surgery. Little data exists on patients' and referring endocrinologists' perspectives of its use. The study aimed to assess and compare endocrine surgery patients' attitudes about telemedicine to that of referring endocrinologists. Method: Patients from a regional endocrine surgery practice and referring endocrinologists were sent surveys about their perspectives on telemedicine use. Results: Fifty two patients responded: average age was 58.3 years; 78% were female; 33% were Black. Sixteen referring endocrinologists responded: average age was 52.4 years; 62.5% were female. Nearly all patients (92%) and providers (100%) would try telemedicine or use it again. Providers were more likely than patients to use telemedicine because of COVID-19 (100% versus 70.6%, P = 0.03). Patients were more concerned about the lack of personal connection with telemedicine than providers (60.8% versus 25.0%, P = 0.02). Endocrinologists were more interested in using telemedicine to review abnormal results (81.3% versus 35.3%, P <0.01), and more patients were specifically disinterested in reviewing abnormal results via telemedicine (54.9% versus 6.3%, P = 0.04). Patients were more interested in its use for postoperative visits (47.1% versus 0%, P <0.01). More endocrinologists were specifically disinclined to conduct new consultations with telemedicine (87.5% versus 58.8%, P <0.01). Conclusion: Telemedicine is a mutually acceptable method for patients and their referring providers for endocrine surgery delivery, although in-person visits continue to have their place. Telemedicine use may continue to expand after the pandemic as an important point of access for endocrine surgery. Keywords: Endocrine surgery; Patient perspectives; Provider perspectives; Telemedicine.

参考サイト PubMed: covid-19


1月 29, 2021 バイオアソシエイツ


マイアミ大学ミラー医学部の研究者らは、臍帯由来の間葉系幹細胞の注入によって最も重症の COVID-19 患者の死亡リスクを安全に減らし、回復までの時間を短縮することを示す、ユニークで画期的なランダム化比較試験を主導した。 STEM CELLS Translational Medicineで2021年1月5日に掲載されたこのオープンアクセス論文は「COVID-19急性呼吸窮迫症候群の臍帯間葉系幹細胞:二重盲検、フェーズ1 / 2a、ランダム化比較試験(Umbilical Cord Mesenchymal Stem…

ゲスト 764人 と メンバー 6人 がオンラインです